Skip to Content
Stock Strategist

Vertex Is a Rare-Disease Powerhouse

The shares currently look undervalued ahead of further drug approval.

Mentioned: , ,

After  Vertex Pharmaceuticals(VRTX) third-quarter results showed robust uptake of cystic fibrosis drugs Orkambi and Kalydeco, we raised our fair value estimate to $175 per share from $170. Our updated 2017 sales estimates fall in line with management’s new outlook: $1.29 billion-$1.32 billion for full-year Orkambi sales (from $1.1 billion-$1.3 billion) and $810 million-$830 million for Kalydeco sales (from $770 million-$800 million). We think the company’s drug portfolio was significantly derisked following the earlier news of positive triple-combination drug data for harder-to-treat cystic fibrosis patients with heterozygous F508del mutations. We believe Vertex’s monopoly in the cystic fibrosis market merits a narrow economic moat rating, and we think the shares are currently undervalued.

Thanks to the approval of Kalydeco in children ages 2 and older in the United States with residual function mutations, the drug’s sales increased 12% quarter over quarter. Once these patients come on line, we believe Kalydeco sales will return to slow but steady growth. Phase 3 data evaluating next-generation corrector tezacaftor in combination with Kalydeco did not show an acute effect on the lung function Kalydeco patients. However, as these patients are already well served by Kalydeco, we don’t believe the finding bears any significance for our model estimates.

Kelsey Tsai does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.